Correlation Between Virax Biolabs and IBio, Common

Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and IBio, Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and IBio, Common into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virax Biolabs Group and iBio, Common Stock, you can compare the effects of market volatilities on Virax Biolabs and IBio, Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of IBio, Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and IBio, Common.

Diversification Opportunities for Virax Biolabs and IBio, Common

-0.76

Correlation Coefficient

Virax Biolabs  IBio, Common

Pay attention - limited upside

The 3 months correlation between Virax and IBio, is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and iBio, Common Stock in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on iBio, Common Stock and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with IBio, Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of iBio, Common Stock has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and IBio, Common go up and down completely randomly.

Pair Corralation between Virax Biolabs and IBio, Common

Given the investment horizon of 90 days Virax Biolabs Group is expected to under-perform the IBio, Common. But the stock apears to be less risky and, when comparing its historical volatility, Virax Biolabs Group is 1.02 times less risky than IBio, Common. The stock trades about -0.09 of its potential returns per unit of risk. The iBio, Common Stock is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  245.00  in iBio, Common Stock on December 27, 2024 and sell it today you would earn a total of  196.00  from holding iBio, Common Stock or generate 80.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Virax Biolabs Group  vs.  iBio, Common Stock

Virax Biolabs Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

iBio, Common Stock

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in iBio, Common Stock are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, IBio, Common displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Virax Biolabs and IBio, Common

The main advantage of trading using opposite Virax Biolabs and IBio, Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, IBio, Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IBio, Common will offset losses from the drop in IBio, Common's long position.

The idea behind Virax Biolabs Group and iBio, Common Stock pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.